Acura Pharmaceuticals Stock Performance
| ACUR Stock | USD 0.0005 0.00 0.00% |
Acura Pharmaceuticals holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.96, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Acura Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, Acura Pharmaceuticals is expected to outperform it slightly. Use Acura Pharmaceuticals jensen alpha, value at risk, as well as the relationship between the Value At Risk and skewness , to analyze future returns on Acura Pharmaceuticals.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Acura Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile basic indicators, Acura Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Acura |
Acura Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.02 in Acura Pharmaceuticals on September 26, 2025 and sell it today you would earn a total of 0.03 from holding Acura Pharmaceuticals or generate 150.0% return on investment over 90 days. Acura Pharmaceuticals is currently generating 5.638% in daily expected returns and assumes 35.098% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Acura, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acura Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acura Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Acura Pharmaceuticals, and traders can use it to determine the average amount a Acura Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1606
| Best Portfolio | Best Equity | ACUR | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Acura Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acura Pharmaceuticals by adding it to a well-diversified portfolio.
Acura Pharmaceuticals Fundamentals Growth
Acura OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Acura Pharmaceuticals, and Acura Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acura OTC Stock performance.
| Return On Asset | -0.38 | |||
| Profit Margin | (0.51) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 3.49 M | |||
| Shares Outstanding | 65.09 M | |||
| Price To Earning | 125.00 X | |||
| Price To Book | 24.11 X | |||
| Price To Sales | 1.45 X | |||
| Revenue | 3.57 M | |||
| EBITDA | (633 K) | |||
| Cash And Equivalents | 89 K | |||
| Total Debt | 105 K | |||
| Debt To Equity | 2.40 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (719 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 1.74 M | |||
| Retained Earnings | (418.63 M) | |||
| Current Asset | 14.13 M | |||
| Current Liabilities | 3.24 M | |||
About Acura Pharmaceuticals Performance
Assessing Acura Pharmaceuticals' fundamental ratios provides investors with valuable insights into Acura Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acura Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people.Things to note about Acura Pharmaceuticals performance evaluation
Checking the ongoing alerts about Acura Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Acura Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acura Pharmaceuticals is way too risky over 90 days horizon | |
| Acura Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Acura Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Acura Pharmaceuticals currently holds 105 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharmaceuticals has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 3.57 M. Net Loss for the year was (1.21 M) with profit before overhead, payroll, taxes, and interest of 1.79 M. | |
| Acura Pharmaceuticals currently holds about 89 K in cash with (719 K) of positive cash flow from operations. | |
| Roughly 19.0% of Acura Pharmaceuticals shares are held by company insiders |
- Analyzing Acura Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acura Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acura Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acura Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acura Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Acura Pharmaceuticals' otc stock. These opinions can provide insight into Acura Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acura OTC Stock Analysis
When running Acura Pharmaceuticals' price analysis, check to measure Acura Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharmaceuticals is operating at the current time. Most of Acura Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acura Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acura Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acura Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.